Integrating new targeted agents into the treatment of non-small-cell lung cancer.
AffiliationChristie and Wythenshawe Hospitals, Manchester, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractLung cancer is the most common cause of cancer-related deaths worldwide, and the discovery and implementation of more effective therapy remains challenging. The development of agents that target the epidermal growth factor receptor/human epidermal growth factor receptor 1 (EGFR/HER1) signal transduction pathway have provided a class of novel targeted therapies that are applicable in the treatment of non-small-call lung cancer (NSCLC). Current challenges include the determination of how best these promising new agents can be integrated into current methods of treatment for patients with NSCLC, and clarification of the extent to which early lines of treatment can influence outcome in the later stages.
CitationIntegrating new targeted agents into the treatment of non-small-cell lung cancer. 2006, 54 Suppl 2:S25-31 Lung Cancer
- Targeted therapies for non-small cell lung cancer.
- Authors: Dempke WC, Suto T, Reck M
- Issue date: 2010 Mar
- New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
- Authors: Crawford J
- Issue date: 2003 Jan
- Targeted therapies in the treatment of non small cell lung cancer: reality and hopes.
- Authors: Gridelli C
- Issue date: 2004 Mar
- Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
- Authors: Burris HA 3rd
- Issue date: 2009 Aug
- Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
- Authors: Patel JD
- Issue date: 2006 Nov